View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
June 15, 2020

Coronavirus company news summary – ams and Senova launch rapid antibody Covid-19 test – Royal Philips adds new technology to aid expectant mothers amid pandemic

By Chloe Kent

Fluidigm Corporation has applied for Emergency Use Authorization (EUA) with the US Food and Drug Administration (FDA) for its extraction-free saliva-based Covid-19 test. The test was developed in partnership with the McDonnell Genome Institute and the Washington University School of Medicine Department of Genetics. The test it is run on the Biomark HD microfluidics platform

ams and Senova are working together on a point-of-care rapid antibody test for Covid-19, which combine Senova technology and ams spectral sensor technology to boost the usability and performance of a lateral flow-based test. The device provides an objective result which requires no user interpretation. In contrast to the established PCR method, the test kit can be applied in doctor’s offices and other point-of-care situations at low cost.

Royal Philips has added a new wireless Avalon CL Fetal and Maternal Pod and Patch to its remote patient monitoring suite, which aids at-risk populations amid the Covid-19 crisis. This new technology reduces the unnecessary physical interactions, which has bee an important measure during the pandemic to limit the spread of the disease. The patch is part of an innovative high-risk pregnancy solution that includes Philips perinatal analytics, visualisation software and a fetal monitor that is ultra-portable and battery-operated.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU